| Bioactivity | HLCL-61 is a first-in-class small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5). |
| Target | Protein arginine methyltransferase 5 |
| Invitro | HLCL-61 (1-100 μM; 24-72 hours) reduces cells growth at dose-dependent manner with IC50s of 14.12, 16.74, 6.3, 8.72 μM for MV4-11 cells, THP-1 cells, FLT3-WT blast, and FLT3-ITD blast, respectively[1].HLCL-61 shows effective inhibition of symmetric arginine dimethylation (me2) of histones H3 and H4 in AML samples, starting at 12 h post-treatment and persisting after 48 h[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> HLCL-61 相关抗体: Cell Viability Assay[1] Cell Line: |
| CAS | 586395-74-6 |
| Formula | C23H24N2O |
| Molar Mass | 344.45 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tarighat SS, et al. The dual epigenetic role of PRMT5 in acute myeloid leukemia: gene activation and repression via histone arginine methylation. Leukemia. 2016 Apr;30(4):789-99. |